Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

Quach, H; Joshua, D; Ho, J; Szer, J; Spencer, A; Harrison, S; Mollee, P; Roberts, A; Horvath, N; Talaulikar, D; To, B; Zannettino, A; Brown, R; Catley, L; Augustson, B; Jaksic, W; Gibson, J; Prince, HM

Author(s): Quach, H; Joshua, D; Ho, J; Szer, J; Spencer, A; Harrison, S; Mollee, P; Roberts, A; Horvath, N; Talaulikar, D; To, B; Zannettino, A; Brown, R; Catley, L; Augustson, B; Jaksic, W; Gibson, J; Prince, HM;
Details: Publication Year 2015-03,Volume 45,Issue #3,Page 335-43
Journal Title: Intern Med J
Publication Type: Journal Article
Abstract: Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.
Publisher: Wiley
Research Division(s): Cancer And Haematology
PubMed ID: 25735577
Publisher's Version: https://doi.org/10.1111/imj.12688
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2015-05-19 02:05:29

Last Modified: 2015-05-19 03:28:38